↓ Skip to main content

Advances and Challenges on Management of Gastrointestinal Stromal Tumors

Overview of attention for article published in Frontiers in oncology, May 2018
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (56th percentile)

Mentioned by

twitter
3 X users
facebook
1 Facebook page

Citations

dimensions_citation
42 Dimensions

Readers on

mendeley
32 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Advances and Challenges on Management of Gastrointestinal Stromal Tumors
Published in
Frontiers in oncology, May 2018
DOI 10.3389/fonc.2018.00135
Pubmed ID
Authors

Lin Mei, Wei Du, Michael Idowu, Margaret von Mehren, Sosipatros A. Boikos

Abstract

Gastrointestinal stromal tumors (GISTs) originate from interstitial cells of Cajal and account for over 5,000 newly diagnosed cases in the United States. The discovery of activated KIT and PDGFRA mutations and introduction of imatinib revolutionized the treatment strategy and opened up the new era of target therapy for solid tumors. Although surgery remains the primary modality of treatment for curative purpose, almost half of the patients experienced disease recurrence. Tailoring (neo)-adjuvant treatment with imatinib is ongoing to meet the need for an effective therapy. Currently, two drugs (sunitinib and regorafenib) have obtained Food and Drug Administration approval for GISTs after imatinib failure. However, most of the patients eventually progress due to primary or secondary resistance. Deeper understanding of the molecular mechanisms will guide us to develop personalized strategies in the future. Discussion in this review includes current standard management and the most recent advances and multiple ongoing clinical trials with different approaches. This review will provide further steps to be taken to conquer refractory disease.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 32 100%

Demographic breakdown

Readers by professional status Count As %
Other 7 22%
Researcher 6 19%
Student > Ph. D. Student 3 9%
Student > Bachelor 2 6%
Student > Postgraduate 2 6%
Other 3 9%
Unknown 9 28%
Readers by discipline Count As %
Medicine and Dentistry 12 38%
Biochemistry, Genetics and Molecular Biology 5 16%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Chemical Engineering 1 3%
Immunology and Microbiology 1 3%
Other 3 9%
Unknown 9 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 June 2019.
All research outputs
#15,523,434
of 25,382,440 outputs
Outputs from Frontiers in oncology
#4,863
of 22,428 outputs
Outputs of similar age
#187,458
of 341,525 outputs
Outputs of similar age from Frontiers in oncology
#66
of 153 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,428 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 341,525 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 153 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.